Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: The sysucc-002 randomized clinical trial.

被引：10
|
作者：
Yuan, Zhongyu
Huang, Jia-Jia
Hua, Xin
Zhao, Jian-Li
Lin, Ying
Zhang, Yuan-Qi
Wu, Zhiyong
Zhang, Lehong
Bi, Xiwen
Xia, Wen
Zhong, Yong-Yi
Wang, Shu-Sen
Xu, Fei
Hong, Ruoxi
Jiang, Kuikui
Shi, Yanxia
Xue, Cong
An, Xin
机构：
[1] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Canc Ctr, Dept Med Oncol, Guangzhou, Guangdong, Peoples R China
[3] State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China
[4] Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
[5] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China
[6] Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China
[7] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Breast Oncol, Guangzhou, Peoples R China
[8] Guangdong Med Univ, Affiliated Hosp, Guangzhou, Peoples R China
[9] Shantou Cent Hosp, Dept Breast Surg, Shantou, Peoples R China
[10] Guangzhou Med Univ, Affiliated Hosp 2, Guangzhou, Peoples R China
[11] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China
[12] Sun Yat Sen Univ, Ctr Canc, Dept Med, State Key Lab Oncol South China,Collaborat Innova, Guangzhou, Peoples R China
[13] Sun Yat Sen Univ, Ctr Canc, Dept Oncol, State Key Lab Oncol South China,Collaborat Innova, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.1003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1003
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Trastuzumab combined with doublet or single-agent chemotherapy as a first-line treatment for HER2-positive metastatic breast cancer.
    Yu, Yunfang
    Wang, Ying
    Chen, Kai
    Fu, Tuping
    Yao, Herui
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [32] LapatinibIn Postmenopausal Women with Hormone Receptor-Positive, HER2-Positive Metastatic Breast Cancer
    Monique P. Curran
    Drugs, 2010, 70 : 1411 - 1422
  • [33] Trastuzumab therapy in HER2-positive, metastatic breast cancer
    Smith, A. D.
    Guilbert, K.
    Lister, D.
    Streilein, S.
    Bourrier, V. C.
    Lozar, B.
    Navaratnam, S.
    Harding, G. A.
    Pitz, M. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [34] First-line ribociclib plus endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled efficacy analysis
    Tripathy, D.
    Hortobagyi, G.
    Chan, A.
    Im, S-A
    Chia, S.
    Yardley, D.
    Esteva, F. J.
    Hurvitz, S.
    Kong, O.
    Bao, W.
    Lorenc, K. Rodriguez
    Diaz-Padilla, I.
    Slamon, D. J.
    CANCER RESEARCH, 2019, 79 (04)
  • [35] registHER: Treatment outcomes in patients with HER2-positive (HER2+), hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Tripathy, D.
    Kaufman, P.
    Brufsky, A.
    Mayer, M.
    Yood, M.
    Wang, L.
    Brammer, M.
    Yardley, D.
    Tan-Chiu, E.
    Rugo, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [36] Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trial
    Yabing Zheng
    Wen-Ming Cao
    Xiying Shao
    Yanxia Shi
    Li Cai
    Wenyan Chen
    Jian Liu
    Peng Shen
    Yiding Chen
    Xian Wang
    Huiping Li
    Man Li
    Zhanhong Chen
    Xiaojia Wang
    Nature Communications, 14
  • [37] Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trial
    Zheng, Yabing
    Cao, Wen-Ming
    Shao, Xiying
    Shi, Yanxia
    Cai, Li
    Chen, Wenyan
    Liu, Jian
    Shen, Peng
    Chen, Yiding
    Wang, Xian
    Li, Huiping
    Li, Man
    Chen, Zhanhong
    Wang, Xiaojia
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [38] Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer
    Farhat, Fadi
    Kattan, Joseph G.
    Ghosn, Marwan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (05) : 1069 - 1077
  • [39] An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer
    Cardoso, Fatima
    Canon, Jean-Luc
    Amadori, Dino
    Aldrighetti, Daniela
    Machiels, Jean-Pascal
    Bouko, Yasmina
    Verkh, Lev
    Usari, Tiziana
    Kern, Kenneth A.
    Giorgetti, Carla
    Dirix, Luc
    BREAST, 2012, 21 (06): : 716 - 723
  • [40] Evaluation of trastuzumab, docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer
    Wardley, A.
    Anton-Torres, A.
    Pivot, X.
    Morales-Vasquez, F.
    Dias, Zetina L.
    Gaui, M.
    Otero Reyes, D.
    Jassem, J.
    Button, P.
    Bell, R.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S33 - S33
12345